1. Alas S, Bonavida B, Emmanouilides C (2000) Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab. Anticancer Res 20: 2961–2966
2. Boue F, Gabarre J, Gisselbrecht C, Reynes J, Plantier I, Morlat P, Milpied N, Raphael M, Lancar R, Costagliola D (2002) CHOP chemotherapy plus rituximab in HIV patients with high grade lymphoma–results of an ANRS Trial. Blood 100: 470a (abstract 1824)
3. Brugger W, Hirsch J, Repp R, Grünebach F, Schlimok G, Vogel W, Kopp HG, Manz M, Brossart P, Aulitzky W, Ganser A, Gramatzki M, Fehnle K, Kanz L (2002) Treatment of follicular and mantle cell lymphoma with rituximab after high-dose chemotherapy and autologous blood stem cell transplantation: A Multicenter Phase II Study. Blood 100: 644a (abstract 2532)
4. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo-Lopez AJ, Rosenberg J, Kunkel L, Flinn IW (2001) Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 19: 2153–2164
5. Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA (2003) Randomized phase II study of concurrent versus sequential treatment with rituximab with fludarabine in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: superior complete response rate with concurrent therapy. Blood 101: 6–14